The FDA on December 19, 2017 granted regular approval to CABOMETYX® for treatment of patients with advanced Renal Cell Carcinoma (RCC). CABOMETYX® is a product of Exelixis, Inc.
Other Pages – Bottom Ad
Advertisement
Subscribe
Other Pages – Top Ad
Advertisement